Kunal Dhamesha · Macquarie
directIndia business growth and weakness in cardiac and gastrointestinal segments.
Yes, so indeed, if you take out all the other categories which outperform the market, and actually all of them would have a digit beside these two segments, as for both of them, there are solutions in terms of, let's call it, the actual execution of the way we do sales and marketing, as well as the product performance per se. Specifically to gastro, I have no doubt that it will come relatively soon. Cardiovascular may take an additional quarter as we need some more adjustments to do.
Kunal Dhamesha · Macquarie
directEconomics and launch sequence for denosumab biosimilar.
Yes, that's how we should look at it. So denosimab is actually supposed to facilitate our abatacept launch because the two products are going for the same segments and give or take to the same type of purpose. So it was also the strategic rationale of why to license the product.
Neha Manpuria · Bank of America
directReason for decline in US base business excluding Revlimid.
So nothing major happened. The products that were declined were the famous products that we got in the competition, like the Ciprodex and the Suboxone. The stuff that the competition entered, some of them nine months ago, some of them six months ago. So there was a certain continuation.
Neha Manpuria · Bank of America
directInvestment and ramp-up timeline for NRT business post-acquisition.
We do have an agreement with them on investment and increase of even investment in certain areas. This is a business that actually is now gaining momentum. It is growing actually for the second year in a row, and we want to continue that momentum, so there is a certain agreement of gross to net, how much market expenses we should put at the time.
Amey Chalke · JM Financial
directCompetitive scenario and market dynamics for semaglutide in Canada.
First, the product, if I recall correctly, January 26 is where the patent expiration will happen for Ozempic. And this is the product that the generic version of it is expected to be launched. If we will get approval, I believe we are positioned well to get approval for that period of time. And naturally, it is a very important market for us.
Amey Chalke · JM Financial
directCapacity and execution readiness for semaglutide supply.
We are working on this project, including capacity for the last 10 years. It's not that 10 years ago, we knew that the product would be that big. This is obviously information that came over time. But if you see the level of R&D and CapEx, you can assume that a big portion of it went for this activity.
Amey Chalke · JM Financial
partialDiscretionary SG&A spend and sustainability post-Revlimid.
So, let me take it. I mentioned in the past, we feel very, very comfortable with 25% EBITDA, which allows us to, and we mentioned it in the past, allow us to give a greater return to the shareholders as well as allow us to invest in the system. Absolutely, we took advantage of the fact that we had a few years of generic Revlimid, and we absolutely took it to invest more.
Bino Pathiparampil · Elara Capital
directIron sucrose filing status and expected approval timeline.
So we filed it actually a long time ago. We recently got a CR on the API side, which we are planning to address. So we thought that it would be good to launch it in these coming months. This right now will be delayed because we need to answer this CR.
Bino Pathiparampil · Elara Capital
directConfidence in abatacept biosimilar approval despite past competitor failures.
We had a very successful phase one. And so far, normally when you pass phase one, you have a good chance to, of course, be very successful in phase three. Also, so far, the rollout and the fact that we even finished the rollout, all the patients is very encouraging.
Bino Pathiparampil · Elara Capital
partialLenalidomide revenue trajectory post-settlement volume restrictions ending.
I don't know exactly how the quarters will be because this is a decision normally by the customers. It's not that we are planning that way. We are serving the customer in the way they want to be served. But yeah, we likely that we will not sell in this level of pricing, let's say post somewhere September, maybe October of calendar 2025.
Surya Patra · PhillipCapital
directProfitability outlook for NRT portfolio acquisition.
It should continue to be profitable. So we are absolutely going to finance the additional investment with growth, and we are planning to keep it profitable. There is no plan now to go for, let's say, two, three years of investment and then take it from there.
Surya Patra · PhillipCapital
directTimeline for Nestlé Health Science to contribute meaningfully to domestic growth.
So the question on Nestlé, this will absolutely going to take time. The reason for that is that we need to bring the products to India, and we need to invest behind brands that are not today recognized in India. ... But in terms of significant contribution to the growth, it will take a couple of years.
